STRZ vs CURI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

STRZ

32.4
AI Score
VS
CURI Wins

CURI

35.2
AI Score

Investment Advisor Scores

STRZ

32score
Recommendation
AVOID NEW MONEY

CURI

35score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric STRZ CURI Winner
Forward P/E 3.5907 8.0645 STRZ
PEG Ratio 0 0 Tie
Revenue Growth 0.5% 22.3% CURI
Earnings Growth 0.0% 1400.0% CURI
Tradestie Score 32.4/100 35.2/100 CURI
Profit Margin -23.6% 0.0% CURI
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

STRZ 1M: +4.9% · 3M: +4.2% CURI 1M: -13.9% · 3M: -13.9%

Current Technical Phase

STRZ

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 60

RSI (14): 59.9 · Price: $26.06

CURI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 35

RSI (14): 35.2 · Price: $2.41

Fundamentals Snapshot

Metric STRZ CURI
Market Cap — —
Forward P/E 3.6 7.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.2%
Gross Margin 0.6% 0.6%
Operating Margin -0.1% 0.4%
EPS -16.76 0.00
Dividend Yield — 0.13%

Frequently Asked Questions

Based on our detailed analysis, CURI is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.